AA
GALT icon

Apriem Advisors’s Galectin Therapeutics GALT Stock Holding History

Apriem Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,600
Closed -$8K – 528
2014
Q3 		$8K Buy
+1,600
New +$12.5K ﹤0.01% 397

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apriem Advisors's GALT Position: Q4 2014 in Review

Apriem Advisors sold out of Galectin Therapeutics (GALT) in Q4 2014, closing a stake of 1,600 shares — an estimated $8K sold.

Apriem Advisors first reported a position in GALT in Q3 2014 and held it in 1 quarter. The position peaked at $8K in Q3 2014. 62 funds tracked by Wall St. Rank hold GALT as of Q4 2014.

  • Apriem Advisors reported no remaining Galectin Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Apriem Advisors sold 1,600 Galectin Therapeutics shares in Q4 2014, an estimated $8K.
  • Apriem Advisors first reported a position in Galectin Therapeutics in Q3 2014 and held it in 1 quarter.
  • Apriem Advisors's Galectin Therapeutics position peaked at $8K in Q3 2014.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2014.

Based on Apriem Advisors's 13F filing for Q4 2014, filed 12 Feb 2015.